Douglas Losordo
Equibles does not estimate personal net worth.
About Douglas Losordo
Douglas Losordo was last confirmed as Board Member at Longeveron Inc. (LGVN) in a filing dated April 28, 2023. Cadrenal Therapeutics, Inc. reported in an 8-K filed February 7, 2025 that Douglas Losordo was terminated as Chief Medical Officer, effective February 4, 2025. The proxy statement of Cadrenal Therapeutics, Inc. reports total compensation of $528,690 for Douglas Losordo in fiscal 2023, including a base salary of $401,026. Disclosed compensation is on record for 5 fiscal years.
“On February 4, 2025, the Company terminated its employment relationship with its Chief Medical Officer, Douglas Losordo, on a mutual amicable basis.”
Affiliation history
-
Cadrenal Therapeutics, Inc. (CVKD)
Proxy statement
Start not stated–2024-06-11
Last confirmed by a filing; no departure on record
-
Start not stated–2023-04-28
Last confirmed by a filing; no departure on record
-
Lisata Therapeutics, Inc. (LSTA)
Proxy statement
Start not stated–2020-11-12
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Cadrenal Therapeutics, Inc. (CVKD) | Chief Medical Officer | $401,026 | $528,690 |
| 2022 | Cadrenal Therapeutics, Inc. (CVKD) | Chief Medical Officer | — | $648,560 |
| 2020 | Lisata Therapeutics, Inc. (LSTA) | Former Chief Medical Officer | $412,360 | $712,890 |
| 2019 | Lisata Therapeutics, Inc. (LSTA) | Former Chief Medical Officer | $443,415 | $890,011 |
| 2018 | Lisata Therapeutics, Inc. (LSTA) | Chief Medical Officer | $441,263 | $1,012,429 |